Bitter Pills:Medicines & The Third World Poor | Page 226

35

Others may put the question differently. For example, D.W. McMullan of Beecham writes:
"It is unlikely that the pricing of Pharmaceuticals to Third World countries will ever be seen
as fair to all interested parties. One must remember that, if the pharmaceutical industry is
to flourish, it must make a profit. However, it is a matter of debate whether a patient for example
in the UK or in Germany should subsidise the price of medicines to a patient in Bangladesh
or Poland." (Personal communication, 22 March 1982.)

36

-

Dr. Michael W. Hodin, Director of Public Affairs Pfizer International Inc., personal
communication, 17 March 1982.
Financial Times Survey, op.cit.

37

-

Alex Lumbroso, Managing Director, Laboratories Mariceau SA, "The Introduction of
New Drugs", in Blum, Herxheimer, Stenzl and Woodcock (ed), Pharmaceuticals and
Health Policy, 1981, p.63.
International Herald Tribune, May 25, 1981.
More recently the Financial Times reports that Smith-Kline "almost trebled its sales
between 1976and last year." R&Dspendingin 1981 was 120 million dollars and operating
profit that year 525.8 million dollars. ( F.T. Survey, op.cit.)

38

Financial Times Survey, op.cit.

39

Drs. J. P. Griffin and G.E. Diggle, UK DHSS Medicines Divison, review of ten years licensing
experience quoted in SCRIP No.633, 12 October 1981, p.2.

40

FDA Bureau of Drugs New Drug Evaluation Project, Briefing book, October 1979, Table
IV-i, quoted by Brudon, 1981, op.cit., p.226. Similarly in France according to Lumbroso out
of about 250 drugs in each year, "only 5 are innovations of any therapeutic interest". (Lumbroso
in Blum, et al. (ed), 1981, op.cit., p.62.)

41

SCRIP, No. 633, op.cit.

42

David Taylor, Deputy Director Office of Health Economics, Medicines Health and the Poor
World, OHE, London 1982, p.35.

43

Ibid.

44

Lesley Doyal with Imogen Pennell, The Political Economy of Health, Pluto Press 1979. p.269.

45

"Roche and its fight against tropical diseases", translation (by Roche) of article in Roche
Magazine, No.4, August 1978.

46

Ibid.

47

Ibid.

48

-

Prof. G. Peters, Univeristyof Lausanne, "Rapport MissionauMozambique", 1981, p8.
Dr. Milton Silverman, University of California, personal communication, 10 August
1981.

49

-

Wellcome, In Pursuit of Excellence, One Hundred Year Book 1880- 1980, pp.49-58.
R. Lassere, "The Swiss Pharmaceutical Industry and Tropical Diseases", Roche
translation of article in Therapeutische Umschau, 36 (1979) Part 3, pp. 263-266.
And "Practical Roche responses to the special needs of Developing Countries", attachment
6 to personal communication from S. Redfern, Roche Products Ltd., 13 April 1982.

50

Peter Cunliffe, President of the Association of the British Pharmaceutical Industry and
Chairman of the Pharmaceutical Division of ICI Ltd., text of paper "Pharmaceuticals in the
Third World", present VBF